

such that the resulting complex can bind to and autophosphorylate ret receptor protein tyrosine kinase.

The presently claimed nucleotide and polypeptide sequences were not described or suggested in the cited art before the priority date of the present application. For the foregoing reasons and in view of the amendments, Applicants respectfully request consideration of present claims. Applicants' representative would appreciate the opportunity to talk with the Examiner, in person or by telephone, to discuss any remaining questions and facilitate the prosecution and allowance of the application or to place the case in better form for appeal.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Daniel R. Curry". The signature is fluid and cursive, with a stylized "C" at the end.

Daniel R. Curry  
Attorney for Applicants  
Registration No.: 32,727  
Phone: (805) 447-8102  
Date: August 26, 1999

Please send all future correspondence to:

U.S. Patent Operations/DRC  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1789